Copyright
©The Author(s) 2021.
World J Gastrointest Oncol. Dec 15, 2021; 13(12): 1850-1862
Published online Dec 15, 2021. doi: 10.4251/wjgo.v13.i12.1850
Published online Dec 15, 2021. doi: 10.4251/wjgo.v13.i12.1850
Ref. | Year | Study population | Study design | Location of obstructive cancer | Survival outcome |
Matsuda et al[75] | 2015 | n = 1136: (1) BTS = 432; and (2) ES = 704 | Meta-analysis: (1) 2 RCTs; (2) 2 prospective nonrandomized comparative studies; and (3) 7 retrospective comparative studies | Right- and left-sided | (1) No difference in disease-free survival and overall survival; and (2) No difference in recurrence |
Ceresoli et al[76] | 2017 | n = 1333: (1) BTS = 688; (2) ES = 655 | Meta-analysis: (1) 5 RCTs; (2) 3 prospective nonrandomized comparative studies; and (4) 9 retrospective comparative studies | Left-sided | (1) No difference in local recurrence and overall recurrence; (2) No difference in 3-yr and 5-yr recurrence; and (3) No difference in 3-yr and 5-yr mortality |
Yang et al[53] | 2018 | n = 497: (1) BTS = 251; and (2) ES = 246 | Meta-analysis: 8 RCTs | Left-sided | Higher tumor recurrence rate in BTS with an odds ratio of 1.79, 95%CI: 1.09–2.93 |
Amelung et al[51] | 2018 | n = 1919: (1) BTS = 938; and (2) ES = 981 | Meta-analysis: (1) 5 RCTs; (2) 4 prospective nonrandomized comparative studies; and (3) 12 retrospective comparative studies | Left-sided | (1) No difference in locoregional recurrence and overall recurrence; (2) No difference in 3-yr and 5-yr disease-free survival; and (3) No difference in 3-yr and 5-yr overall survival |
Foo et al[54] | 2019 | n = 448: (1) BTS = 222; and (2) ES = 226 | Meta-analysis: 7 RCTs | Left-sided | (1) Overall recurrence rate: 37.0% in BTS vs 25.9% in ES; (2) The risk ratio of systemic recurrence 1.627 for BTS; and (3) No difference in 3-yr overall survival and disease-free survival |
Arezzo et al[52] (ESCO trial) | 2020 | n = 115: (1) BTS = 56; and (2) ES = 59 | RCT | Left-sided | No difference in 3-yr overall survival, time to progression, and disease-free survival |
- Citation: Yoo RN, Cho HM, Kye BH. Management of obstructive colon cancer: Current status, obstacles, and future directions. World J Gastrointest Oncol 2021; 13(12): 1850-1862
- URL: https://www.wjgnet.com/1948-5204/full/v13/i12/1850.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v13.i12.1850